Stable pentadecapeptide therapy counteracts gentamicin-induced nephrotoxicity via nitric oxide-system modulation: evidence from a triple nitric oxide-agent approach in rats.

Animal study investigating BPC 157 therapy and nitric oxide agents in rats with gentamicin-induced nephrotoxicity

“In rats, stable gastric pentadecapeptide (BPC 157) therapy may resolve severe gentamicin nephrotoxicity (100 mg/kg ip/daily through 8 days) and the nitric oxide (NO)-system relation.”

Rats

“In rats, stable gastric pentadecapeptide (BPC 157) therapy may resolve severe gentamicin nephrotoxicity (100 mg/kg ip/daily through 8 days) and the nitric oxide (NO)-system relation.”

8 days

“In rats, stable gastric pentadecapeptide (BPC 157) therapy may resolve severe gentamicin nephrotoxicity (100 mg/kg ip/daily through 8 days) and the nitric oxide (NO)-system relation.”

BPC 157 therapy counteracted gentamicin nephrotoxicity clinical presentation, serum urea, and creatinine levels

“BPC 157 therapy counteracted gentamicin nephrotoxicity clinical presentation (i.e., close to normal), serum urea, and creatinine (i.e., values close to normal preserved), maintained diuresis (polyuria/oliguria completely avoided), and no renal mass increase.”

Microscopy showed fully preserved normal tubular epithelium cells and nephron presentation

“Finally, fully preserved normal tubular epithelium cells and nephron presentation were present in the microscopy.”

BPC 157 regimens overwhelmed the effects of the NO-agents

“BPC 157 regimens (peroral or intraperitoneal) overwhelmed these NO-agents' effects.”